XML 42 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaboration and Other Agreements - Background Narrative (Details) (USD $)
1 Months Ended 3 Months Ended
Dec. 31, 2011
Mar. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum total excess amounts plus interest $ 225,000,000pcyc_MaximumTotalExcessAmountsPlusInterest  
Incremental interest rate for excess amount 2.00%pcyc_IncrementalInterestRateForExcessAmount  
Maximum Percentage Of Interest On Outstanding Excess Amount (In Percent) 5.00%pcyc_MaximumPercentageOfInterestOnOutstandingExcessAmountInPercent  
Maximum interest on excess amount 25,000,000pcyc_MaximumInterestOnExcessAmount  
Estimated weighted average cost of capital (in percent) 12.00%us-gaap_FairValueInputsDiscountRate  
Minimum license royalty rates (in percent) 30.00%pcyc_MinimumLicenseRoyaltyRatesInPercent  
Maximum license royalty rates (in percent) 40.00%pcyc_MaximumLicenseRoyaltyRatesInPercent  
Janssen [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Sharing percentage pre-tax profit 50.00%pcyc_CollaborativeArrangementCostsAssociatedwithCommercialization
/ us-gaap_CounterpartyNameAxis
= pcyc_JanssenMember
 
Total excess amounts funded by Janssen   139,200,000pcyc_TotalExcessAmountsFundedByOutsideEntityIncludingInterest
/ us-gaap_CounterpartyNameAxis
= pcyc_JanssenMember
Total Excess Amounts Funded by Janssen   134,300,000pcyc_TotalExcessAmountsFundedByOutsideEntity
/ us-gaap_CounterpartyNameAxis
= pcyc_JanssenMember
Interest on Outstanding Excess Amount   4,900,000pcyc_InterestonOutstandingExcessAmount
/ us-gaap_CounterpartyNameAxis
= pcyc_JanssenMember
Pharmacyclics, Inc. [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Sharing percentage pre-tax profit 50.00%pcyc_CollaborativeArrangementCostsAssociatedwithCommercialization
/ dei_LegalEntityAxis
= pcyc_PharmacyclicsInc.Member
 
Licenses [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Non-Refundable Upfront Payment Upon Execution 70,600,000pcyc_NonRefundableUpfrontPaymentUponExecution
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_LicensesMember
 
Committee Services [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Non-Refundable Upfront Payment Upon Execution 15,000,000pcyc_NonRefundableUpfrontPaymentUponExecution
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_CommitteeServicesMember
 
Services revenue recognized period 17 years  
Development Services [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Non-Refundable Upfront Payment Upon Execution 64,400,000pcyc_NonRefundableUpfrontPaymentUponExecution
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_DevelopmentServicesMember
 
Services revenue recognized period 9 years  
Collaboration and License Agreement with Janssen Biotech Inc [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Non-Refundable Upfront Payment Upon Execution 150,000,000pcyc_NonRefundableUpfrontPaymentUponExecution
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
 
Maximum milestone payments 825,000,000pcyc_MaximumMilestonePayments
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
 
Percent of cost sharing arrangement Janssen share 60.00%pcyc_PercentOfCostSharingArrangementJanssenShare
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
 
Percent of cost sharing arrangement by company 40.00%pcyc_PercentOfCostSharingArrangementByPcyc
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
 
Company's annual cap of development costs 50,000,000pcyc_MaximumCostSharingAmountIncurred
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
50,000,000pcyc_MaximumCostSharingAmountIncurred
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
Collaboration Agreement, Number of Days to Reimburse Collaborative Partner for Outstanding Excess Amounts After Change of Control 30 days  
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Continued Development Progress [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum milestone payments 250,000,000pcyc_MaximumMilestonePayments
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_ContinuedDevelopmentProgressMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
 
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Achievement of Regulatory Progress [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum milestone payments 225,000,000pcyc_MaximumMilestonePayments
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_AchievementOfRegulatoryProgressMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
220,000,000pcyc_MaximumMilestonePayments
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_AchievementOfRegulatoryProgressMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
Cumulative milestone payments triggered under collaboration   605,000,000pcyc_RevenueRecognitionMilestoneMethodCumulativeRevenueRecognized
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_AchievementOfRegulatoryProgressMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Regulatory Approval [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum milestone payments $ 350,000,000pcyc_MaximumMilestonePayments
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= pcyc_RegulatoryApprovalMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CollaborationAndLicenseAgreementWithJanssenBiotechIncMember